



PRESS RELEASE

Perspixon Biotech wins Life Sciences Europe award

Frankfurt, June 2023

Perspixon Biotech was awarded as "Top Biotherapeutics Company 2023" by the Life Sciences Review Europe. The award comprises a recognition for Perspixon's contribution to tackling customer challenges in biopharma R&D.

The reasons for being awarded as top biotherapeutics company 2023 comprise:

- Perspixon's crucial role in generating multi-dimensional data sets for complex molecules addressing multiple diseases,
- Perspixon's contribution to making the process of developing multi-specific antibody therapeutics more efficient and cost-effective, and
- Perspixon's ambition to become the first truly predictive AI drug-design company based on its roPROTix development platform.

A complete article about Perspixon and its innovative and unique roPROTix platform is featured in the current edition of the Life Sciences Review Europe as well as in the [online edition](#).

"We are very excited about being recognized and supported in our mission to emerge as a biotherapeutics company making cost-effective biomedicines available for millions of patients," say Dr. Matthias Wiedenfels, CEO.

Perspixon's next steps are focused on finding appropriate industry partners and investors in their roPROTix platform.

For further media information/interview opportunities please contact:

Dr. José Airas

T +49 (0)177 577 9828

E info@perspixonbio.tech

Notes to editors:

Perspixon is a biotech company specialized in multi-specific antibodies. Perspixon creates next-generation biotherapeutics through an end-to-end automated discovery platform. The company aims to radically accelerate the technical development of biological drug modalities with predictive AI, significantly reducing drug development times and costs. The roPROTix platform automatically generates tens of thousands of in-silico designed modalities and analyses them for key functional and biophysical properties in a parallelized approach. This digitally integrated process generates interrelated and multidimensional datasets of unprecedented quantity and quality, which feed directly into ML algorithms that drive the in-silico design engine.

Perspixon is headquartered in the FIZ Frankfurt Innovation Center for Biotechnology, Germany